Remove 2007 Remove Physicians Remove Safety
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires.

article thumbnail

Japan’s M&A Boom

Pharmaceutical Technology

“The Japanese government is encouraging physicians to use more generic drugs,” Sato explains, adding that this is in part due to the ageing population and increased price of effective healthcare. “Ranbaxy led the way with eight acquisitions and is aspiring to be a $2bn company by 2007.” % increase).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK approves prescription-only melatonin drug for childhood ADHD

Pharmaceutical Technology

In July 2019, the MHRA held up Colonis for sending a letter to physicians advertising the off-label use of the drug in children and those with renal impairment. However, the UK’s Electronic Medicines Compendium (EMC) states that “the safety and efficacy of Circadin in children aged 0 to 18 years has not yet been established.”

article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Help physicians to better understand the medicines and, by that means, prescribe them. Founded in 2007 by Peter Gassner, a luminary of Silicon Valley with a net worth of circa $5.25 The race for relevance is on. How can you become more relevant? Veeva Systems – a journey from Silicon Valley into the life sciences.

Pharma 98